Home/Filings/4/0001179110-20-010056
4//SEC Filing

KWON YOUNG 4

Accession 0001179110-20-010056

CIK 0001235010other

Filed

Sep 30, 8:00 PM ET

Accepted

Oct 1, 5:05 PM ET

Size

48.9 KB

Accession

0001179110-20-010056

Insider Transaction Report

Form 4
Period: 2020-10-01
KWON YOUNG
SVP, Corporate Development
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-10-0196,8630 total
    Exercise: $31.87Exp: 2030-02-07Common Stock (96,863 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2020-10-012,8190 total
    Common Stock (2,819 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-10-016,7120 total
    Exercise: $13.02Exp: 2025-02-18Common Stock (6,712 underlying)
  • Disposition to Issuer

    Common Stock

    2020-10-01160,6330 total
  • Disposition to Issuer

    Restricted Stock Unit

    2020-10-0131,5000 total
    Common Stock (31,500 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-10-013,4660 total
    Exercise: $17.96Exp: 2024-02-18Common Stock (3,466 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-10-013,2140 total
    Exercise: $21.56Exp: 2025-08-11Common Stock (3,214 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-10-012,3630 total
    Exercise: $10.83Exp: 2026-02-09Common Stock (2,363 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-10-013,1370 total
    Exercise: $31.87Exp: 2030-02-07Common Stock (3,137 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-10-0138,3340 total
    Exercise: $18.85Exp: 2027-02-07Common Stock (38,334 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-10-01115,6560 total
    Exercise: $12.76Exp: 2029-02-11Common Stock (115,656 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2020-10-0150,0000 total
    Common Stock (50,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-10-016,7660 total
    Exercise: $18.85Exp: 2027-02-07Common Stock (6,766 underlying)
  • Disposition to Issuer

    Restricted Stock Unit

    2020-10-0145,0000 total
    Common Stock (45,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-10-018,5020 total
    Exercise: $13.26Exp: 2021-02-22Common Stock (8,502 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-10-0135,4370 total
    Exercise: $10.83Exp: 2026-02-09Common Stock (35,437 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-10-013,5720 total
    Exercise: $12.58Exp: 2023-02-19Common Stock (3,572 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-10-0119,3440 total
    Exercise: $12.76Exp: 2029-02-11Common Stock (19,344 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-10-017,2280 total
    Exercise: $12.58Exp: 2023-02-19Common Stock (7,228 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-10-011,3560 total
    Exercise: $17.96Exp: 2024-02-18Common Stock (1,356 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-10-0113,0130 total
    Exercise: $13.02Exp: 2025-02-18Common Stock (13,013 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-10-016,7860 total
    Exercise: $21.56Exp: 2025-08-11Common Stock (6,786 underlying)
Footnotes (3)
  • [F1]Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.
  • [F2]Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price.
  • [F3]Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

Issuer

MOMENTA PHARMACEUTICALS INC

CIK 0001235010

Entity typeother

Related Parties

1
  • filerCIK 0001733094

Filing Metadata

Form type
4
Filed
Sep 30, 8:00 PM ET
Accepted
Oct 1, 5:05 PM ET
Size
48.9 KB